To identify genes dysregulated in bipolar disorder (BD1), we carried out global gene expression profiling using whole-genome microarrays. To minimize genetic variation in gene expression levels between cases and controls, we compared expression profiles in lymphoblastoid cell lines from monozygotic twin pairs discordant for the disease. We identified 82 genes that were differentially expressed by X1.3-fold in three BD1 cases compared to their co-twins, and which were statistically (Pp0.05) differentially expressed between the groups of BD1 cases and controls. Using quantitative reverse transcriptasepolymerase chain reaction, we confirmed the differential expression of some of these genes, including: KCNK1, MAL, PFN2, TCF7, PGK1 and PI4KCB, in at least two of the twin pairs. In contrast to the findings of a previous study by Kakiuchi and colleagues with similar discordant BD1 twin design, our data do not support the dysregulation of XBP1 and HSPA5. From pathway and gene ontology analysis, we identified upregulation of the WNT signalling pathway and the biological process of apoptosis. The differentially regulated genes and pathways identified in this study may provide insights into the biology of BD1.
Introduction
The causes of bipolar disorder (BD) are as yet unknown, thus greatly limiting the possibilities for treatment and management of risk factors. However, it is evident that genetics plays a key role in susceptibility to BD. 1 The increased concordance rates between monozygotic (MZ) twins compared to dizygotic (DZ) twins for BD is a major line of evidence, implicating genetic risk factors. BD concordance rates between MZ twins vary between 43 and 79%, 2, 3 with high estimates of heritability being reported (89 4 -93% 3 ). Intuitively, the brain is the target organ for investigations into gene expression differences associated with BD, however, this limits studies to the use of post-mortem brain tissue. There are several challenges in generating and replicating expression findings in post-mortem brain: (1) restricted access to large cohorts; (2) choice of appropriate brain region for investigation; (3) the heterogeneity of cell types within brain tissue and (4) effects on gene expression caused by death and/or post-death handling of tissue. 5 These variables, as well as age, race and gender, introduce factors which can produce large variations, resulting in very little overlap when comparing findings across studies. These difficulties are further compounded by variations introduced by the use of different microarray platforms. Other cell types such as peripheral blood leukocytes (PBLs), [6] [7] [8] lymphoblastoid cell lines (LCLs) 1, 9 and olfactory epithelium (OE) 10 have emerged as alternative tissue resources that have many comparable underlying molecular pathways as the brain. In a recent paper, Sullivan and coworkers compared global gene expression of blood and brain. 11 They showed that blood gene expression profiles shared significant similarity to 16 regions of the central nervous system (CNS). Importantly, they identified the gene ontology (GO) categories that were similar, and different, between tissues. Many processes showed very little to no difference between tissues and therefore demonstrate that blood gene expression profiles can be used as an alternative more accessible tissue resource with similarity to CNS-derived tissue. Most of the GO categories that were vastly different were unique white blood cell functions. Detection of morphological, physiological and molecular differences in cultured LCLs, fibroblasts and OE from patients with mental illnesses supports the existence of disease-related biology in tissues other than brain. [12] [13] [14] This provides an excellent opportunity for further investigating the cellular defects underlying neurological diseases, allowing the recruitment of larger sample sizes as well as samples based on hypothesis-driven ascertainment, for example, families and twins.
Experimental designs using twins continue to be a powerful tool for the investigation of hereditary traits. The mechanism behind incomplete disease concordance between MZ twins remains poorly understood. Epigenetic factors are a more commonly detected source of variation between MZ twins and are an attractive mechanism for the observed phenotypic differences. 15, 16 The role of epigenetic regulation of gene expression in complex diseases, including psychiatric disorders is attracting increasing molecular and epidemiological support. 17 The use of twins also increases capacity over population-based studies to conduct multivariate analyses to decipher complex relationships between genes and pleiotropic effects. 18, 19 A significant challenge in the application of high-throughput expression profiling of unrelated individuals is the inherent variation due to differences in genetic, ethnic and demographic variables. [20] [21] [22] Clearly, a twin study design offers significant advantages in dealing with these sources of variation in disease genetics. It is thus surprising that the molecular genetic potential of disease-discordant twins has not been tapped to a larger degree in the neuropsychiatric field. We are aware of only one study that has exploited a discordant twin design in probing psychiatric illness using microarray gene expression analysis. 1 Kakiuchi and colleagues assessed gene expression differences in LCLs derived from two pairs of monozygotic twins that were discordant for BD1 using gene arrays comprised of 12 626 elements. Using an arbitrary cutoff of 1.6-fold, they found 17 genes (1 up-and 16 downregulated) differentially expressed in both twin pairs, including XBP1 and HSAPA5, which are involved in endoplasmic reticulum (ER) stress response signalling. They provided functional support for these genes being induced to a lesser degree following stimulation of the ER stress response in individuals with BD1 compared to healthy controls and found that the degree of induction of XBP1 was associated with a single nucleotide polymorphism (SNP) in the putative promoter of the gene. This SNP was found to be significantly overrepresented in BD1 in a Japanese case-control sample and was transmitted preferentially to offspring affected with BD1 in a sample of BD1 trios of mixed genetic background from the National Institute of Mental Health (NIMH). However, subsequent typing of this SNP in a much larger family-based sample from the NIMH and in three case-control samples from Europe failed to replicate the putative association between XBP1 genotype and predisposition to BD1. 23 Kakiuchi et al. followed up their initial findings with HSPA5 and found a particular haplotype of this gene was significantly associated with BD1 in the Japanese population, but not the NIMH family-based samples. 1 The authors conclude that interindividual variability in ER stress response contributes to BD1 susceptibility, but to date these findings await replication.
We sought to replicate and extend the microarray findings of Kakiuchi et al.
1 by analysing three MZ twin pairs discordant for BD1 using Affymetrix whole-genome arrays comprising 56 675 elements.
Materials and methods

Subjects
Participants were recruited as part of the Australian Twins and Psychosis Study, through referrals from treating clinicians, mental health clinics, family organizations and the Australian Twin Registry. For the microarray part of this study, one male and two female pairs of MZ twins discordant for BD with psychotic features (BD1) were recruited. For affected cases, all diagnoses were made according to the Diagnostic and Statistical Manual of Mental Disorders, fourth edition (DSM-IV). 24 Diagnostic assessment was comprehensive, and based on the Diagnostic Interview for Genetic Studies, 25 available medical records and on information from a family informant using the Family Interview for Genetic Studies. 26, 27 All information was reviewed independently by two research psychiatrists, who then met to assign a consensus Best Estimate Final Diagnosis. 28 Details of the MZ twin pairs are presented in Table 1 . Unaffected twins were recontacted 3 years after initial diagnostic assessment in order to confirm their unaffected status. Zygosity of the twins was assessed using an AmpFLSTR Profiler Plus PCR Amplification Kit (Applied Biosystems, Foster City, CA, USA), and data was analyzed using Genescan v3.7.1 software (Applied Biosystems) and Genotyper v2.5 software (Applied Biosystems).
Sample preparation
LCLs were established by Epstein-Barr virus (EBV) transformation of lymphocytes as described. 29 To limit any cell culture effects on gene transcription levels cell lines were all grown under tightly controlled growth conditions in the same batch of RPMI (Sigma-Aldrich, Castle Hill, NSW, Australia) 1640 medium with 10% fetal bovine serum and antibiotics prior to RNA extraction. When cells were in log phase growth, they were pelleted and washed with phosphate-buffered saline, and total RNA was extracted using Qiagen RNeasy Midi Kits (Qiagen, Doncaster, VIC, Australia) as per the manufacturer's instructions. RNA quality was monitored using an Agilent 2100 bioanalyzer (Agilent Technologies, Forest Hills, VIC, Australia) and expressed as an RNA integrity number (RIN) value. All samples had an RIN of 9.9 or 10, which designates very high quality RNA according to the grading (on an ascending quality scale of 1-10) of Agilent 2100 RIN Software (Agilent Technologies) (data not shown).
Microarray hybridization
Expression profiles were generated by hybridizing 5 mg of total RNA to Affymetrix Human Genome U133 plus 2.0 Gene Chips, Affymetrix, Santa Clara, CA, USA (HG U133plus 2.0) according to the Affymetrix Eukaryote One-cycle protocol. Briefly, 5 mg of total RNA were used to generate biotinylated cRNA, which was fragmented and hybridized to a chip for 16 h at 451C in an Affymetrix Hybridization Oven 640. Arrays were then washed and stained on an Affymetrix Fluidics Station 450 and subsequently scanned on an Affymetrix GeneChip Scanner 3000 to obtain fluorescence intensities. Gene expression data from this twin cohort is available at the Gene Expression Omnibus website (http://www.ncbi.nlm.nih.gov/geo/) under accession number GSE7036.
Data analysis
Relative expression values were generated for each transcript using the Affymetrix MAS5.0 algorithm in GeneChip Operating Software (GCOS) Version 1.2, with the average intensity of all transcripts on each array scaled to 150 so that the same target signal across all arrays could be compared. MAS5-processed data was then imported into GeneSpring 7.2 software (Agilent Technologies), where the data were analysed in two separate ways: (1) differences between the affected and unaffected twin of each pair and (2) differences between all affected twins as a group versus all controls as a group. For part (1), each pair of twins was imported as an individual experiment and the unaffected twin was normalized to the median of both twins, and the affected co-twin was normalized against the median of the unaffected co-twin. Since the number of discordant twins was low, and because we wanted to compare each affected twin specifically to his/her unaffected co-twin, we did not apply statistical criteria to determine differential gene expression within a twin pair, but rather assessed the fold-change difference in transcript abundance for each gene between the co-twins, similar to the approach used by Kakiuchi et al. 1 For part (2) , all samples were imported as a single experiment and per chip (each measurement was divided by the 50th percentile of all present measurements in that sample) and per gene (each gene was divided by the median of its measurements in all samples) normalization was performed. Data were then filtered for transcripts that were present across all samples and with expression values above that of global error calculated by the cross-gene error model. 30 Since the cell type under study is a virus-transformed B-lymphocyte, and different subclones of B-cells could be randomly (a) infected with EBV and (b) selected in culture, all immunoglobulin and B-cellrelated genes were removed from analysis, since any apparent differences in the expression of these are more likely to be an artefact of the system used rather than the disease under investigation. A similar strategy to this was used by Kakiuchi et al.
1 for analysis of LCL-derived microarray data. Hierarchical clustering was performed on the filtered gene list using standard Pearson correlation (around zero) in GeneSpring. Differential gene expression between cases and controls was assessed by applying a Welch's approximate t-test (variances not equal) with significance set at P value less than 0.05.
Functional annotation analysis, including pathway and ontology was performed using the Web-accessible bioinformatics software package DAVID 2006 . 31 This program uses a modified Fisher's exact P-value (EASE score) to rank gene clusters by statistical overrepresentation of individual genes, based on the cooccurrence/enrichment of the category within the gene list relative to all genes in the same category on the array. 31 Pathway analysis maps gene products from the lists to BioCarta and KEGG pathways, and GO analysis maps gene products GO to categories as provided by Gene Ontology Consortium. To avoid potentially spurious associations when categories had low numbers of members, we only considered categories in which more than two genes were found to be significantly differentially expressed, that is, using the default EASE-score cutoff of 0.1 for DAVID 2006 analysis. Comparison of microarray data to that of Kakiuchi et al.
1
We generated fold-change data from our MZ twin pairs for each of the 17 genes reported to be different in BD1 by Kakiuchi et al. 1 Conversely, we obtained fold-change data from Kakiuchi and coworkers for the two MZ twin pairs discordant for BD they studied, for the genes we found to be differentially expressed in BD1 taken from Tables 4A and 5 . For these genes, the microarray data was normalized and analysed in the same way as described above for our data.
Results
Of the 56 675 transcripts on the HG U133plus 2.0 Gene Chip, 1393 were removed for being immunoglobulin or B-cell-related (see Materials and methods section and Kakiuchi et al. 1 ). Of the remainder, 17 684 were determined to be expressed in 100% of samples with a relative expression value greater than the global-error calculated value of 43. Cluster analysis on the filtered gene list (Figure 1 ) showed the extremely high similarity of each twin pair's expression profiles, with all of the twin pairs clustering next to each other, indicating the high degree of heritability underlying gene expression levels. For each twin pair, transcripts were selected if their expression in the affected twin was X1.3-fold that of the unaffected twin. This level of fold-change threshold was selected because it was well above the technical reproducibility of the Affymetrix platform, and it has also been used by others to identify differentially expressed genes in BD1. 33 A gene was determined to have altered expression in BD1 if it showed a X1.3-fold expression difference, in the same direction, in all three twin pairs. At a fold-change cutoff of 1.3, there were 269 genes differentially expressed in all three discordant twin pairs (see Supplementary Table 2) . Within this list, eight genes were differentially expressed in all three discordant twin pairs at a fold-change cutoff of 2.0 and 62 genes at a fold-change cutoff of 1.5.
For part (2) of the data analysis, treating samples as unrelated individuals, the expression of three BD1 patients was compared to three healthy co-twin controls by the Welch's t-test, which detected 292 genes as being differentially expressed at Pp0.05 (Supplementary Table 3 ). Cluster analysis shows a clear discrimination between the BD1 patient samples and control samples based on this small number of genes (Supplementary Figure 1) .
The lists generated by both analysis methods (fold change and statistical test) were compared to obtain a highly robust list of 82 genes that displayed both a X1.3-fold change in all three twin pairs and which were statistically (Pp0.05) differentially expressed between BD1 and controls ( Table 2) . On this list, only one gene is located on the X chromosome, and due to the mixed sex of the three twin pairs, it is unlikely that random X chromosome inactivation is confounding the results.
DAVID 2006 pathway analyses were conducted on the 63 known genes from the list of 82 genes above (33 upregulated and 30 downregulated in BD1), but due to the small size of the lists, no statistically significant pathway was returned. We next carried out GO analyses on the same list. There were eight significant GOs in the upregulated genes, the most significant being 'induction of programmed cell death'. There were eight significant GOs in the downregulated genes; the majority of the categories involved metabolism or DNA-related functions (Table 3) .
The three twin pairs X1.3-fold-change list (269 genes) and the Welch test P < 0.05 list (292 genes) were also subjected to DAVID 2006 pathway analysis. The WNT signaling pathway was the top overrepresented pathway for both lists (Table 4) , with five genes from this pathway on the fold-change list and eight on the Welch test list. Two of these WNT pathway-related transcripts were in common between these lists.
The three twin pairs X1.3-fold-change list of 269 genes contained 202 known genes (102 upregulated and 100 downregulated in BD1), and these were Table 5 ). Again, 'metabolism' and 'cell death' categories were predominant. Categories involved in protein transport and processing were also overrepresented. We selected eight genes for validation by qRT-PCR, which had high discriminating power (from the list of 82 genes in the overlap between the fold change and statistical analyses) and/or were from a relevant pathway. Comparison of microarray data and qRT-PCR data for these eight genes in the discordant twin pairs is summarized in Table 5 . KCNK1, a gene with a > twofold change in all three twin pairs and statistically significant differential expression in the microarray analysis, displayed a similar pattern of upregulation in all twin pairs by qRT-PCR, although the magnitude of the differences was smaller in each case. Likewise, the differentially increased expression of MAL, a gene identified in previous microarray studies, 6 ,34 was confirmed in all three twin pairs, although the increase in TP2 was only marginal (1.1-fold). The high fold-change differences between all three twin pairs for PFN2 determined by the array experiments (1.7-9.6-fold increased) were confirmed by qRT-PCR in all twin pairs except TP2, which showed no difference by qRT-PCR and had the lowest difference (1.7-fold) by microarray. Similar to this, PIK4CB and TCF7 were increased in BD1 in all three twin pairs by microarray but only in two twin pairs by qRT-PCR, with the other pair for PIK4CB showing no change and a slight increase for TCF7 (1.2-fold). The qRT-PCR for PGK1 did not validate the microarray data. All three BD1 twins showed downregulation by microarray, but only two did so by qRT-PCR, and then only marginally so; the other BD1 twin showed no difference.
To provide further support for dysregulation of the WNT pathway in BD1, as well as the involvement of some of the key genes we found to be differentially expressed, we sought to assess the expression of these genes in an independent sample of MZ twin pairs discordant for BD1. This data was taken from the study of Kakiuchi et al. 1 and included additional unpublished data kindly provided by the authors. Of the genes listed in Tables 4A and 5 , only half were represented on the HG_U95A Affymetrix microarray used by Kakiuchi and colleagues. The genes not represented were CCND2, WNT10A, PPP2R1B (from Table 4A ) and PIK4CB, OSBPL11, OSBPL7 (from Table  5 ). Microarrays for the Kakiuchi et al. 1 twin pairs were performed in duplicate, and the mean fold-change values for the genes identified in our study are shown in Table 5 . All 17 genes reported by Kakiuchi et al.
1 as being highly differentially expressed in BD1 were represented on the HG_U133 plus 2 Affymetrix microarray used in our study. None of these genes showed complete concordance in all twin pairs used in the two studies. The fold change of two genes (C6ORF32, ATF5) was in the same direction in two out of three of our twin pairs. For several of the other genes, the fold change was in the same direction in only one of our twin pairs. Table 6 summarizes the fold-change differences for all 17 genes in each twin pair in the two studies.
Discussion
Previous microarray studies using post-mortem brains from BD1 patients have found differential expression of genes related to apoptosis and neuroprotection; 35, 36 neurotransmission and energy metabolism; 37 mitochondrial function; 37, 38 receptor/transport, stress response, molecular chaperones and transcription factors; 33 signal transduction; 33, 35 myelination and oligodendrocyte function 39 and ubiquitin cycle and synaptic-related genes. 40 Microarray studies assessing white blood cell-derived gene expression levels in BD1 have found, among many different processes, aberrations in RNA binding and ribosomal function, 6 as well as the ER stress response.
1 Similar work using OE has shown perturbations in phosphatidylinositol signalling, catecholamine metabolism, neurogenesis, apoptosis and cell proliferation. 10 In the present study, we sought to extend these findings using a discordant MZ twin experimental design to analyse gene expression differences in LCLs derived from BD1 patients and their unaffected 'identical' co-twin.
Our findings support the dysregulation of some of the above pathways in BD1.
Dysregulated WNT signalling in BD1
Pathway analysis revealed dysregulation of five genes involved in WNT signalling on the fold-change list and eight genes on the Welch test list. Two genes overlapped in both lists, encoding transcription factor 7 (T-cell specific, HMG-box) and protein phosphatase 2 (formerly 2A) regulatory subunit A (PR 65), beta isoform. Two of the three WNT signalling genes: wingless-type MMTV integration site family, member 10A and calcyclin binding protein, which were only on the fold-change list, had suggestive P-values for differential expression of 0.1 or below. Cyclin D2, the remaining gene, had a P-value of 0.4. Three of the six WNT signalling genes: protein kinase, cAMP-dependent, catalytic, beta; E1A binding protein p300; mitogen-activated protein kinase 8; which were only on the statistical Welch P < 0.05 list were found to be upregulated more than 1.3-fold in two of the three twin pairs. The constitutively active enzyme, GSK3b is key regulator of the WNT signalling pathway. Signalling through the WNT/frizzled receptor complex inhibits GSK3b activity, which in turn results in activation of several downstream cellular signalling cascades. GSK3b is of considerable interest to BD1 research, since evidence that lithium, and to a lesser extent sodium valproate, has an inhibitory effect on GSK3b, leading to a suggested neuroprotective role (reviewed in Quiroz et al.
41
). Upregulation of the WNT signaling pathway, as seen in this study, could be abrogated by treatment with lithium or valproate. The patients with BD1 in this study were being treated with lithium or valproate at the time of sampling, however, contact between the drug and the cells would have been lost through the process of isolation, EBV transformation and cell culture. Thus the only way that the drug could have an influence on Table 4A .
gene expression measured here by microarrays is if it caused a lasting epigenetic modification to the chromatin of the patients' cells -something for which there is no empirical evidence to date.
Altered apoptotic signaling in BD1
Overexpression of the WNT signalling pathway through the inhibition of GSK3b can drive intracellular signalling towards cell death. From ontology analysis of the highly robust list of 82 genes (33 known genes upregulated) that displayed both a X1.3-fold change in all three twin pairs and which were statistically (P < 0.05) differentially expressed between BD1 patients and controls, we found an increase in expression of three genes designated as having 'apoptosis regulator activity': protein phosphatase 2 (formerly 2A), regulatory subunit A (PR 65), beta isoform; nonmetastatic cells 3; protein expressed in mal, T-cell differentiation protein. We found four additional apoptosis genes that showed an increased fold change in the twin pair analysis and 10 others in the case-control comparison. Increased expression of these proapoptotic factors is consistent with a post hoc analysis of expression profiles on post-mortem brains, which found 19/44 apoptosis transcripts upregulated in BD1. 36 Functionally, this is also supported by higher rates of apoptosis observed in OE cultures from BD1 cases. 10 Dysregulation of this process could lead to increased neuronal death, which could underlie the pathophysiology of BD1.
Comparison of our findings with those of Kakiuchi et al. Overall, there was no complete concordance between any of the 17 most highly differentially expressed genes in the two pairs of discordant BD1 twins studied by Kakiuchi et al. 1 and the three twin pairs analyzed here (Table 6 ). At best, when considering a fold-change minimum of X1.3 in our data, there were two genes (C6ORF32, ATF5) that showed the same direction of gene expression difference in two out of three of our twin pairs, with the direction of change in the two twin pairs from the work of Kakiuchi et al. 1 Of potential interest here is ATF5, a related family member to ATF6 which is involved in the transcriptional regulation of ER response genes, such as XBP1 and HSPA5.
1
Although there is no direct evidence to indicate a role for ATF5 in regulating the ER stress response, this transcription factor is known to directly interact with the g-aminobutyric acid B receptor 1 42 and the product of the putative schizophrenia susceptibility locus disrupted-in-schizophrenia (DISC1). 43 Although highly speculative, either of these molecular interactions could conceivably contribute to the development of BD1 through altered neuronal signalling.
The concordance between the genes identified in our study and their expression in the two twin pairs discordant for BD1 assessed by Kakiuchi et al.
1 was relatively high. Two genes, PGK1 and SIP, showed complete concordance in all twin pairs tested. Three genes MAL, PFN2 and TCF7 displayed similar foldchange direction in four of the five twin pairs. We identified five members of the WNT signalling pathway (Table 4A ) upregulated in patients with BD1, two of these genes, SIP and TCF7 were represented on the microarray used by Kakiuchi et al., and both genes were similarly upregulated in the affected twins, replicating our data.
Comparison of findings from this study with microarray studies in BD1 Although little overlap was observed between the individual genes identified in this study and previously published studies using microarrays to investigate BD1, there was some concordance with the identified GO categories. Two studies have implicated apoptosis dysregulation in BD1 (discussed above). Additionally, from a recent study using orbitofrontal cortex from post-mortem brains, 40 downregulation of genes involved in the ubiquitin cycle were found. We have seven genes involved in the ubiquitin cycle on the 1.3-fold down GO list (P = 0.07) and 15 genes on the Welch test list (P = 0.01). Ryan et al. 40 also found downregulation of intracellular transport genes. This GO was statistically overrepresented (P = 0.002) in our study, with 19 genes being differentially expressed. Expression of six genes involved in intracellular transport was decreased more than 1.3-fold in all three BD1 twins.
Strengths and limitations of the study This exploratory study has identified candidate genes and pathways, which may be important in the cause and treatment of BD1, however, the data should be interpreted cautiously. Although MZ twin pairs discordant for disease are a powerful research tool, they are very rare, which limits the size, and hence power, of such studies. Another limitation of MZ twin studies of BD1 is the fact that BD1 is likely to be heterogeneous disease. Thus the differences observed here may not apply to all cases of BD. This limitation affects all studies and can only be overcome by very large case-control comparisons. However, case-control studies using gene expression analyses are limited in that they do not take into consideration the underlying genetic variation seen for all genes across the general population, or the notion that different threshold levels of gene expression for disease association pertain to each individual. The advantage of the MZ twin design we have used here was specifically to circumvent this limitation as it primarily considered differences in expression values between genetically identical twin pairs discordant for BD1. It should also be noted that at the time of sampling, the twin pairs were discordant for BD1; however, this does not guarantee that they may not become concordant for BD1 later in life. Since epigenetic profiles in MZ twins deviate with age, 44 the differences present at the time of blood sampling are likely to be relevant for the observed discordance regardless of age. Another limitation encountered in all gene expression studies is the lack of perfect correlation between the microarray and qRT-PCR results. As also seen in this study, the fold-change differences between the affected and unaffected twins for some genes selected for validation were less than that capable of being robustly detected using qRT-PCR. 45 
Conclusions
Using a discordant MZ twin design to minimize genetic variation in gene expression levels between cases and controls, we compared global gene expression profiles in LCLs from three BD1 patients with their corresponding unaffected co-twins. As expected, using unsupervised methods, the three pairs of co-twins clustered together, indicating the high degree of genetic control over transcription. Because each twin pair is genetically identical, the only differences that develop between them with age are epigenetic variations. We hypothesized that some epi-modifications, which result in differences in gene expression, are thus responsible for the observed discordance in disease manifestation. Using whole-genome microarrays, we identified 82 genes that were robustly differentially expressed in the same direction by X1.3-fold in all three BD1 cases compared to their co-twins and were differentially expressed (Pp0.05) between the groups of BD1 cases and controls. These included KCNK1, MAL, PFN2, TCF7 and PI4KCB, which we verified to be differentially expressed in at least two of the twin pairs by qRT-PCR. These genes, and others on the foldchange list, should be considered candidate genes in the etiology of BD1 and thus warrant further assessment as such by additional studies. Additional support for the genes was obtained from an independent set of MZ twins discordant for BD1. Furthermore, from pathway and ontology analysis, we identified the WNT signalling pathway to be dysregulated in BD1. Two of these WNT pathway genes identified in this study were also tested in an independent set of two MZ twin pairs discordant for BD1 and found to be similarly differentially expressed, providing further support for the dysregulation of this pathway in BD1. Therapeutical targeting of this molecular axis may therefore be beneficial for treating this disease.
